U.S.-based medical and cannabis operator, Curaleaf, finds itself in more problems since the Food and Drug Administration (FDA) publicized that the firm was making unsubstantial health claims about its products. While the CuraLeaf did remove all claims after being warned by the federal agency, it has now been accused of violating federal securities law. Simply put, Curaleaf’s health claims is reasoned as a securities violation because the spreading of falsified material is trusted as a scheme to increase the firm’s securities market prices.
